Breast Cancer Clinical Practice Guidelines in OncologyNCCN Categories of Evidence and ConsensusCategory 1: The recommendation is based on high-level evidence (e.g., randomized controlled trials) and there is uniform NCCN consensus.Category 2A: The recommendation is based on lower-level evidence and there is uniform NCCN consensus.Category 2B: The recommendation is based on lower-level evidence and there is nonuniform NCCN consensus (but no major disagreement).Category 3: The recommendation is based on any level of evidence but reflects major disagreement.All recommendations are category 2A unless otherwise noted.The Breast Cancer Clinical Practice Guidelines presented here are the work of the members of the NCCN Breast Cancer Clinical Practice Guidelines Panel. Categories of evidence were assessed and are noted on the algorithms and in the text. Although not explicitly stated at every decision point of the Guidelines, patient participation in prospective clinical trials is the preferred option of treatment for all stages of breast cancer. The full breast cancer guidelines are not printed in this issue of JNCCN, but can be accessed online at www.nccn.org.Clinical trials: The NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.OverviewThe American Cancer Society estimated that 184,450 new cases of invasive breast cancer would be diagnosed and 40,930 patients would die of the disease in the United States in 2008.1 In addition, approximately 67,770 women will be diagnosed with carcinoma in situ of the breast during the same...

If the inline PDF is not rendering correctly, you can download the PDF file here.

  • 1

    Jemal A, Siegel R, Ward E. Cancer statistics, 2008. CA Cancer J Clin 2008;58:7196.

  • 2

    Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:16871717.

    • Search Google Scholar
    • Export Citation
  • 3

    Gail MH, Costantino JP, Bryant J. Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst 1999;91:18291846.

    • Search Google Scholar
    • Export Citation
  • 4

    Dupont WD, Page DL. Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 1985;312:146151.

  • 5

    White J, Morrow M, Moughan J. Compliance with breast-conservation standards for patients with early-stage breast carcinoma. Cancer 2003;97:893904.

    • Search Google Scholar
    • Export Citation
  • 6

    Wilkinson NW, Shahryarinejad A, Winston JS. Concordance with breast cancer pathology reporting practice guidelines. J Am Coll Surg 2003;196:3843.

    • Search Google Scholar
    • Export Citation
  • 7

    Giordano SH, Valero V, Buzdar AU, Hortobagyi GN. Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 2002;25:235237.

  • 8

    Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. Ann Intern Med 2002;137:678687.

  • 9

    Gundry KR. The application of breast MRI in staging and screening for breast cancer. Oncology (Williston Park) 2005;19:159169; discussion 170, 173–154, 177.

    • Search Google Scholar
    • Export Citation
  • 10

    Esserman L. Integration of imaging in the management of breast cancer. J Clin Oncol 2005;23:16011602.

  • 11

    Houssami N, Ciatto S, Macaskill P. Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol 2008;26:32483258.

    • Search Google Scholar
    • Export Citation
  • 12

    Fischer U, Zachariae O, Baum F. The influence of preoperative MRI of the breasts on recurrence rate in patients with breast cancer. Eur Radiol 2004;14:17251731.

    • Search Google Scholar
    • Export Citation
  • 13

    Solin LJ, Orel SG, Hwang WT. Relationship of breast magnetic resonance imaging to outcome after breast-conservation treatment with radiation for women with early-stage invasive breast carcinoma or ductal carcinoma in situ. J Clin Oncol 2008;26:386391.

    • Search Google Scholar
    • Export Citation
  • 14

    Members of the Breast Cancer Disease Site Group. Program in evidence-based care: a Cancer Care Ontario Program. Baseline staging tests in primary breast cancer. Practice guideline report #1-14. April 30, 2003. Available at: http://www.cancercare.on.ca/pdf/pebc1-14f.pdf. Accessed October 3, 2007.

    • Search Google Scholar
    • Export Citation
  • 15

    Puglisi F, Follador A, Minisini AM. Baseline staging tests after a new diagnosis of breast cancer: further evidence of their limited indications. Ann Oncol 2005;16:263266.

    • Search Google Scholar
    • Export Citation
  • 16

    Kumar R, Chauhan A, Zhuang H. Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat 2006;98:267274.

    • Search Google Scholar
    • Export Citation
  • 17

    Wahl RL, Siegel BA, Coleman RE, Gatsonis CG. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET study group. J Clin Oncol 2004;22:277285.

    • Search Google Scholar
    • Export Citation
  • 18

    Podoloff DA, Advani RH, Allred C. NCCN Task Force Report: PET/CT scanning in cancer. J Natl Compr Canc Netw 2007;5(Suppl 1):S124.

  • 19

    Carr CE, Conant EF, Rosen MA. The impact of FDG PET in the staging of breast cancer [abstract]. J Clin Oncol 2006:24:18 (Suppl 1):Abstract 530.

    • Search Google Scholar
    • Export Citation
  • 20

    Khan QJ, O’Dea AP, Dusing R. Integrated FDG-PET for initial staging of breast cancer [abstract]. J Clin Oncol 2007;25:18(Suppl 1):Abstract 558.

    • Search Google Scholar
    • Export Citation
  • 21

    Rosen EL, Eubank WB, Mankoff DA. FDG PET, PET/CT, and breast cancer imaging. RadiGraphics 2007;27:S215229.

  • 22

    Wang S, Saboorian MH, Frenkel E. Laboratory assessment of the status of Her-2/neu protein and oncogene in breast cancer specimens: comparison of immunohistochemistry assay with fluorescence in situ hybridisation assays. J Clin Pathol 2000;53:374381.

    • Search Google Scholar
    • Export Citation
  • 23

    DAKO HercepTest [package insert]. Carpinteria, CA: DAKO Corp; 2004.

  • 24

    Pathway HER2 [package insert]. Tucson, AZ: Ventana Medical Systems, Inc.; 2004.

  • 25

    INFORM HER2/neu gene detection system [package insert]. Tucson, AZ: Ventana Medical Systems, Inc.; 2001.

  • 26

    PathVysion HER2/neu method [package insert]. Downers Grove, IL: Vysis, Inc.; 2001.

  • 27

    SPOT-Light HER2 CISH kit [package insert]. Camarillo, CA: Invitrogen Corp.; 2008.

  • 28

    Anderson S, Gilkerson E, Klein P. Concordance between local labs and a central lab using FISH and IHC for HER2 testing [abstract]. Breast Cancer Res Treat 2002;76:S68:Abstract 235.

    • Search Google Scholar
    • Export Citation
  • 29

    Paik S, Bryant J, Tan-Chiu E. Real-world performance of HER2 testing—National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002;94:852854.

    • Search Google Scholar
    • Export Citation
  • 30

    Paik S, Tan-Chiu E, Bryant J. Successful quality assurance program for HER2 testing in the NSABP trial for herceptin. Breast Cancer Res and Treat 2002;76(Suppl):S31.

    • Search Google Scholar
    • Export Citation
  • 31

    Perez EA, Suman VJ, Davidson NE. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 Intergroup adjuvant trial. J Clin Oncol 2006;24:30323038.

    • Search Google Scholar
    • Export Citation
  • 32

    Tubbs RR, Pettay JD, Roche PC. Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol 2001;19:27142721.

    • Search Google Scholar
    • Export Citation
  • 33

    Press MF, Sauter G, Bernstein L. Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials. Clin Cancer Res 2005;11:65986607.

    • Search Google Scholar
    • Export Citation
  • 34

    Carlson RW, Moench SJ, Hammond MEH. HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw 2006;4(Suppl 3):S122.

    • Search Google Scholar
    • Export Citation
  • 35

    Wolff AC, Hammond ME, Schwartz JN. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007;25:118147.

    • Search Google Scholar
    • Export Citation
  • 36

    Cooke T, Reeves J, Lanigan A, Stanton P. HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol 2001;12(Suppl 1):S2328.

  • 37

    Paik S, Bryant J, Park C. ErbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst 1998;90:13611370.

    • Search Google Scholar
    • Export Citation
  • 38

    Paik S, Bryant J, Tan-Chiu E. HER2 and choice of adjuvant chemotherapy for invasive breast cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-15. J Natl Cancer Inst 2000;92:19911998.

    • Search Google Scholar
    • Export Citation
  • 39

    Piccart MJ, Di Leo A, Hamilton A. HER2 a ‘predictive factor’ ready to use in the daily management of breast cancer patients? Eur J Cancer 2000;36:17551761.

    • Search Google Scholar
    • Export Citation
  • 40

    Thor AD, Berry DA, Budman DR. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer. J Natl Cancer Inst 1998;90:13461360.

    • Search Google Scholar
    • Export Citation
  • 41

    Pritchard KI, Shepherd LE, O’Malley FP. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006;354:21032111.

    • Search Google Scholar
    • Export Citation
  • 42

    Dressler LG, Berry DA, Broadwater G. Comparison of HER2 status by fluorescence in situ hybridization and immunohistochemistry to predict benefit from dose escalation of adjuvant doxorubicin-based therapy in node-positive breast cancer patients. J Clin Oncol 2005;23:42874297.

    • Search Google Scholar
    • Export Citation
  • 43

    Romond EH, Perez EA, Bryant J. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;353:16731684.

    • Search Google Scholar
    • Export Citation
  • 44

    Piccart-Gebhart MJ, Procter M, Leyland-Jones B. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353:16591672.

    • Search Google Scholar
    • Export Citation
  • 45

    Slamon D, Eiermann W, Robert N. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of HER2 positive early breast cancer patients: second interim efficacy analysis [abstract]. Presented at the San Antonio Breast Cancer Symposium; December 10–14, 2006; San Antonio, Texas. Abstract 52.

    • Search Google Scholar
    • Export Citation
  • 46

    Joensuu H, Kellokumpu-Lehtinen PL, Bono P. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809820.

    • Search Google Scholar
    • Export Citation
  • 47

    Cobleigh MA, Vogel CL, Tripathy D. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999;17:26392648.

    • Search Google Scholar
    • Export Citation
  • 48

    Slamon DJ, Leyland-Jones B, Shak S. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783792.

    • Search Google Scholar
    • Export Citation
  • 49

    Vogel CL, Cobleigh MA, Tripathy D. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719726.

    • Search Google Scholar
    • Export Citation
  • 50

    Allred DC, Harvey JM, Berardo M. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1999;11:155168.

    • Search Google Scholar
    • Export Citation
  • 51

    Rhodes A, Jasani B, Barnes DM. Reliability of immunochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000;53:125130.

    • Search Google Scholar
    • Export Citation
  • 52

    Rudiger T, Höfler H, Kreipe HH. Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol 2002;26:873882.

    • Search Google Scholar
    • Export Citation
  • 53

    Arriagada R, Le MG, Rochard F, Contesso G. Conservative treatment versus mastectomy in early breast cancer: patterns of failure with 15 years of follow-up data. Institut Gustave-Roussy Breast Cancer Group. J Clin Oncol 1996;14:15581564.

    • Search Google Scholar
    • Export Citation
  • 54

    Clarke M, Collins R, Darby S. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;366:20872106.

    • Search Google Scholar
    • Export Citation
  • 55

    Fisher B, Anderson S, Bryant J. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347:12331241.

    • Search Google Scholar
    • Export Citation
  • 56

    Veronesi U, Cascinelli N, Mariani L. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;347:12271232.

    • Search Google Scholar
    • Export Citation
  • 57

    McCormick B. Partial-breast radiation for early staged breast cancers: hypothesis, existing data, and a planned phase III trial. J Natl Compr Canc Netw 2005;3:301307.

    • Search Google Scholar
    • Export Citation
  • 58

    Pignol J-P, Olivotto E, Rakovitch WE. Phase III randomized study of intensity modulated radiation therapy vs. standard wedging adjuvant breast radiotherapy. Int J Rad Oncol 2006;66:S1.

    • Search Google Scholar
    • Export Citation
  • 59

    Whelan T, MacKenzie R, Julian J. Randomized trial of breast irradiation schedules after lumpectomy for women with lymph node-negative breast cancer. J Natl Cancer Inst 2002;94:11431150.

    • Search Google Scholar
    • Export Citation
  • 60

    Antonini N, Jones H, Horiot JC. Effect of age and radiation dose on local control after breast conserving treatment: EORTC trial 22881–10882. Radiother Oncol 2007;82:265271.

    • Search Google Scholar
    • Export Citation
  • 61

    Bartelink H, Horiot JC, Poortmans P. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001;345:13781387.

    • Search Google Scholar
    • Export Citation
  • 62

    Jones H, Antonini N, Colette L. The impact of boost dose and margins on the local recurrence rate in breast conserving therapy: results from the EORTC boost-no-boost trial [abstract]. Int J Radiat Oncol Biol Phys 2007;69(3 Suppl):S23.

    • Search Google Scholar
    • Export Citation
  • 63

    Fourquet A, Campana F, Zafrani B. Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25 year follow-up. Int J Radiat Oncol Biol Phys 1989;17:719725.

    • Search Google Scholar
    • Export Citation
  • 64

    Komoike Y, Akiyama F, Iino Y. Ipsilateral breast tumor recurrence (IBTR) after breast-conserving treatment for early breast cancer: risk factors and impact on distant metastases. Cancer 2006;106:3541.

    • Search Google Scholar
    • Export Citation
  • 65

    Zhou P, Gautam S, Recht A. Factors affecting outcome for young women with early stage invasive cancer treated with breast-conserving therapy. Breast Cancer Res Treat 2007;101:5157.

    • Search Google Scholar
    • Export Citation
  • 66

    Golshan M, Miron A, Nixon AJ. The prevalence of germline BRCA1 and BRCA2 mutations in young women with breast cancer undergoing breast-conservation therapy. Am J Surg 2006;192:5862.

    • Search Google Scholar
    • Export Citation
  • 67

    Kroman N, Holtveg H, Wohlfahrt J. Effect of breast-conserving therapy versus radical mastectomy on prognosis for young women with breast carcinoma. Cancer 2004;100:688693.

    • Search Google Scholar
    • Export Citation
  • 68

    Hughes KS, Schnaper LA, Berry D. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med 2004;351:971977.

    • Search Google Scholar
    • Export Citation
  • 69

    Hughes KS, Schnaper LA, Berry D. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer: a report of further follow-up. Presented at the San Antonio Breast Cancer Symposium; December 14, 2006; San Antonio, Texas. Abstract 11.

    • Search Google Scholar
    • Export Citation
  • 70

    Fyles AW, McCready DR, Manchul LA. Tamoxifen with or without breast irradiation in women 50 years of age or older with early breast cancer. N Engl J Med 2004;351:963970.

    • Search Google Scholar
    • Export Citation
  • 71

    Recht A, Come SE, Henderson IC. The sequencing of chemotherapy and radiation therapy after conservative surgery for early-stage breast cancer. N Engl J Med 1996;334:13561361.

    • Search Google Scholar
    • Export Citation
  • 72

    Dubey A, Recht A, Come SE. Concurrent CMF and radiation therapy for early stage breast cancer: results of a pilot study. Int J Radiat Oncol Biol Phys 1999;45:877884.

    • Search Google Scholar
    • Export Citation
  • 73

    Markiewicz DA, Schultz DJ, Haas JA. The effects of sequence and type of chemotherapy and radiation therapy on cosmesis and complications after breast conservation therapy. Int J Radiat Oncol Biol Phys 1996;35:661668.

    • Search Google Scholar
    • Export Citation
  • 74

    Abner AL, Recht A, Vicini FA. Cosmetic results after surgery, chemotherapy, and radiation therapy for early breast cancer. Int J Radiat Oncol Biol Phys 1991;21:331338.

    • Search Google Scholar
    • Export Citation
  • 75

    Lyman GH, Giuliano AE, Somerfield MR. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005;23:77037720.

    • Search Google Scholar
    • Export Citation
  • 76

    Bass SS, Lyman GH, McCann CR. Lymphatic mapping and sentinel lymph node biopsy. Breast J 1999;5:288295.

  • 77

    Cox CE. Lymphatic mapping in breast cancer: combination technique. Ann Surg Oncol 2001;8(9 Suppl):67S70S.

  • 78

    Cox CE, Nguyen K, Gray RJ. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS): why map DCIS? Am Surg 2001;67:513519; discussion 519–521.

    • Search Google Scholar
    • Export Citation
  • 79

    Krag D, Weaver D, Ashikaga T. The sentinel node in breast cancer—a multicenter validation study. N Engl J Med 1998;339:941946.

  • 80

    McMasters KM, Giuliano AE, Ross MI. Sentinel-lymph-node biopsy for breast cancer—not yet the standard of care. N Engl J Med 1998;339:990995.

    • Search Google Scholar
    • Export Citation
  • 81

    O’Hea BJ, Hill AD, El-Shirbiny AM. Sentinel lymph node biopsy in breast cancer: initial experience at Memorial Sloan-Kettering Cancer Center. J Am Coll Surg 1998;186:423427.

    • Search Google Scholar
    • Export Citation
  • 82

    Veronesi U, Paganelli G, Viale G. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349:546553.

    • Search Google Scholar
    • Export Citation
  • 83

    Kuehn T, Vogl FD, Helms G. Sentinel-node biopsy for axillary staging in breast cancer: results from a large prospective German multi-institutional trial. Eur J Surg Oncol 2004;30:252259.

    • Search Google Scholar
    • Export Citation
  • 84

    Mansel RE, Fallowfield L, Kissin M. Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial. J Natl Cancer Inst 2006;98:599609.

    • Search Google Scholar
    • Export Citation
  • 85

    Dupont E, Cox C, Shivers S. Learning curves and breast cancer lymphatic mapping: institutional volume index. J Surg Res 2001;97:9296.

  • 86

    Cox CE, Salud CJ, Cantor A. Learning curves for breast cancer sentinel lymph node mapping based on surgical volume analysis. J Am Coll Surg 2001;193:593600.

    • Search Google Scholar
    • Export Citation
  • 87

    Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer 1992;28A:14151418.

    • Search Google Scholar
    • Export Citation
  • 88

    Kiricuta CI, Tausch J. A mathematical model of axillary lymph node involvement based on 1446 complete axillary dissections in patients with breast carcinoma. Cancer 1992;69:24962501.

    • Search Google Scholar
    • Export Citation
  • 89

    Fisher B, Redmond C, Fisher ER. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674681.

    • Search Google Scholar
    • Export Citation
  • 90

    Alkuwari E, Auger M. Accuracy of fine-needle aspiration cytology of axillary lymph nodes in breast cancer patients. Cancer 2008;114:8993.

    • Search Google Scholar
    • Export Citation
  • 91

    Fisher B, Bryant J, Wolmark N. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:26722685.

    • Search Google Scholar
    • Export Citation
  • 92

    Bear HD, Anderson S, Smith RE. Sequential preoperative or postoperative docetaxel added to preoperative doxorubicin plus cyclophosphamide for operable breast cancer: National Surgical Adjuvant Breast and Bowel Protocol B-27. J Clin Oncol 2006;24:20192027.

    • Search Google Scholar
    • Export Citation
  • 93

    Buzdar AU, Ibrahim NK, Francis D. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol 2005;23:36763685.

    • Search Google Scholar
    • Export Citation
  • 94

    Smith IE, Dowsett M, Ebbs SR. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005;23:51085116.

    • Search Google Scholar
    • Export Citation
  • 95

    Ellis MJ, Coop A, Singh B. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 2001;19:38083816.

    • Search Google Scholar
    • Export Citation
  • 96

    Hellman S. Stopping metastases at their source. N Engl J Med 1997;337:996997.

  • 97

    Overgaard M, Jensen MB, Overgaard J. Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial. Lancet 1999;353:16411648.

    • Search Google Scholar
    • Export Citation
  • 98

    Ragaz J, Olivotto IA, Spinelli JJ. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 2005;97:116126.

    • Search Google Scholar
    • Export Citation
  • 99

    Overgaard M, Hansen PS, Overgaard J. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337:949955.

    • Search Google Scholar
    • Export Citation
  • 100

    Recht A, Edge SB, Solin LJ. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:15391569.

    • Search Google Scholar
    • Export Citation
  • 101

    Theriault R, Buzdar A, Hortobagyi G. Irradiation (XRT) following mastectomy in patients treated with FAC adjuvant therapy—M.D. Anderson experience [abstract]. Proc Am Soc Clin Oncol 1998;17:99a. Abstract 381.

    • Search Google Scholar
    • Export Citation
  • 102

    McGuire SE, Gonzolez-Angulo AM, Huang EH. Postmastectomy radiation improves the outcome of patients with locally advanced breast cancer who achieve a pathologic complete response to neoadjuvant chemotherapy. Int J Radiat Oncol Biol Phys 2007;68:10041009.

    • Search Google Scholar
    • Export Citation
  • 103

    Huang EH, Tucker SL, Strom EA. Postmastectomy radiation improves local-regional control and survival for selected patients with locally advanced breast cancer treated with neoadjuvant chemotherapy and mastectomy. J Clin Oncol 2004;22:46914699.

    • Search Google Scholar
    • Export Citation
  • 104

    Overgaard M, Nielsen HM, Overgaard J. Is the benefit of postmastectomy irradiation limited to patients with four or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol 2007;82:247253.

    • Search Google Scholar
    • Export Citation
  • 105

    Nielsen HM, Overgaard M, Grau C. Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: long-term results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 2006;24:22682275.

    • Search Google Scholar
    • Export Citation
  • 106

    Anderson BO, Masetti R, Silverstein MJ, Oncoplastic approaches to the partial mastectomy: an overview of volume displacement techniques. Lancet Oncol 2005;6:145157.

    • Search Google Scholar
    • Export Citation
  • 107

    Huemer GM, Schrenk P, Moser F. Oncoplastic techniques allow breast-conserving treatment in centrally located breast cancers. Plast Reconstr Surg 2007;120:390398.

    • Search Google Scholar
    • Export Citation
  • 108

    Malycha PL, Gough IR, Margaritoni M. Oncoplastic breast surgery: a global perspective on practice, availability, and training. World J Surg 2008;32:25702577.

    • Search Google Scholar
    • Export Citation
  • 109

    Kaur N, Petit JY. Comparative study of surgical margins in oncoplastic surgery and quadrantectomy in breast cancer. Ann Surg Oncol 2005;12:539545.

    • Search Google Scholar
    • Export Citation
  • 110

    Loprinzi CL, Thome SD. Understanding the utility of adjuvant systemic therapy for primary breast cancer. J Clin Oncol 2001;19:972979.

  • 111

    Ravdin PM, Siminoff LA, Davis GJ. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J Clin Oncol 2001;19:980991.

    • Search Google Scholar
    • Export Citation
  • 112

    Olivotto IA, Bajdik CD, Ravdin PM. Population-based validation of the prognostic model ADJUVANT! for early breast cancer. J Clin Oncol 2005;23:27162725.

    • Search Google Scholar
    • Export Citation
  • 113

    Loprinzi CL, Ravdin PM. Decision-making for patients with early breast cancer: individualized decisions for and by patients and their physicians. J Natl Compr Canc Netw 2003;1:189198.

    • Search Google Scholar
    • Export Citation
  • 114

    Jeffrey SS, Lonning PE, Hillner BE. Genomics-based prognosis and therapeutic prediction in breast cancer. J Natl Compr Canc Netw 2005;3:291300.

    • Search Google Scholar
    • Export Citation
  • 115

    Sorlie T, Perou CM, Tibshirani R. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98:1086910874.

    • Search Google Scholar
    • Export Citation
  • 116

    Perou CM, Jeffrey SS, van de Rijn M. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 1999;96:92129217.

    • Search Google Scholar
    • Export Citation
  • 117

    Sorlie T, Tibshirani R, Parker J. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100:84188423.

    • Search Google Scholar
    • Export Citation
  • 118

    Wang Y, Klijn JG, Zhang Y. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 2005;365:671679.

    • Search Google Scholar
    • Export Citation
  • 119

    van ‘t Veer LJ, Dai H, van de Vijver MJ. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002;415:530536.

  • 120

    van der Vijver MJ, He YD, van’t Veer LJ. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347:19992009.

    • Search Google Scholar
    • Export Citation
  • 121

    Glas AM, Floore A, Delahaye LJ. Converting a breast cancer microarray signature into a high-throughput diagnostic test. BMC Genomics 2006;7:278287.

    • Search Google Scholar
    • Export Citation
  • 122

    Paik S, Shak S, Tang G. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:28172826.

    • Search Google Scholar
    • Export Citation
  • 123

    Paik S, Tang G, Shak S. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:37263734.

    • Search Google Scholar
    • Export Citation
  • 124

    Fan C, Oh DS, Wessels L. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006;355:560569.

  • 125

    Swain SM, Wilson JW, Mamounas EP. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer. J Natl Cancer Inst 2004;96:516523.

    • Search Google Scholar
    • Export Citation
  • 126

    Berry D, Cirrincione C, Henderson IC. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 2006;295:16581667.

    • Search Google Scholar
    • Export Citation
  • 127

    Albain K, Barlow W, O’Malley F. Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal node positive estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: mature outcomes and new biologic correlates on phase III Intergroup trial 0100 [meeting abstract]. Presented at the San Antonio Breast Cancer Symposium; December 8–11, 2004; San Antonio, Texas. Abstract LBA37.

    • Search Google Scholar
    • Export Citation
  • 128

    Early Breast Cancer Trialists’ Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:14511467.

    • Search Google Scholar
    • Export Citation
  • 129

    Berry DA, Muss HB, Thor AD. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol 2000;18:34713479.

    • Search Google Scholar
    • Export Citation
  • 130

    Eppenberger-Castori S, Kueng W, Benz C. Prognostic and predictive significance of ErbB-2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol 2001;19:645656.

    • Search Google Scholar
    • Export Citation
  • 131

    Knoop AS, Bentzen SM, Nielsen MM. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol 2001;19:33763384.

    • Search Google Scholar
    • Export Citation
  • 132

    Mass R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol 2000;27(Suppl):4652; discussion 92–100.

    • Search Google Scholar
    • Export Citation
  • 133

    Pegram MD, Pauletti G, Slamon DJ. HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 1998;52:6577.

    • Search Google Scholar
    • Export Citation
  • 134

    De Laurentiis M, Arpino G, Massarelli E. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 2005;11:47414748.

    • Search Google Scholar
    • Export Citation
  • 135

    Paik S, Shak S, Tang G. Expression of the 21 genes in the Recurrence Score assay and tamoxifen clinical benefit in the NSABP study B-14 of node negative, estrogen receptor positive breast cancer [abstract]. J Clin Oncol 2005;23:16(Suppl 1): Abstract 510.

    • Search Google Scholar
    • Export Citation
  • 136

    Arpino G, Green SJ, Allred DC. HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study. Clin Cancer Res 2004;10:56705676.

    • Search Google Scholar
    • Export Citation
  • 137

    Dowsett M, Allred C, Knox J. Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial. J Clin Oncol 2008;26:10591065.

    • Search Google Scholar
    • Export Citation
  • 138

    Coombes RC, Kilburn LS, Snowdon CF. Survival and safety of exemestane versus tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 2007;369:559570.

    • Search Google Scholar
    • Export Citation
  • 139

    Kaufmann M, Jonat W, Hilfrich J. Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 study. J Clin Oncol 2007;25:26642670.

    • Search Google Scholar
    • Export Citation
  • 140

    Goss PE, Ingle JN, Martino S. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:12621271.

    • Search Google Scholar
    • Export Citation
  • 141

    Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists’ Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:4553.

    • Search Google Scholar
    • Export Citation
  • 142

    Thurlimann B, Keshaviah A, Coates AS. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005;353:27472757.

    • Search Google Scholar
    • Export Citation
  • 143

    Baum M, Budzar AU, Cuzick J. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002;359:21312139.

    • Search Google Scholar
    • Export Citation
  • 144

    Howell A, Cuzick J, Baum M. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365:6062.

    • Search Google Scholar
    • Export Citation
  • 145

    Duffy S, Jackson TL, Lansdown M. The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial: first results of the endometrial sub-protocol following 2 years of treatment. Hum Reprod 2006;21:545553.

    • Search Google Scholar
    • Export Citation
  • 146

    Fallowfield L, Cella D, Cuzick J. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 2004;22:42614271.

    • Search Google Scholar
    • Export Citation
  • 147

    Eastell R, Adams JE, Coleman RE. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008;26:10511057.

    • Search Google Scholar
    • Export Citation
  • 148

    Dowsett M, Cuzick J, Howell A, Jackson I. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the ‘Arimidex and tamoxifen alone or in combination’ (ATAC) trial. Br J Cancer 2001;85:317324.

    • Search Google Scholar
    • Export Citation
  • 149

    Buzdar AU, Guastalla JP, Nabholtz JM. Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial. Cancer 2006;107:472480.

    • Search Google Scholar
    • Export Citation
  • 150

    Mouridsen H, Keshaviah A, Coates AS. Cardiovascular adverse events during adjuvant endocrine therapy for early breast cancer using letrozole or tamoxifen: safety analysis of BIG 1-98 trial. 2007; J Clin Oncol 2007;25:57155722.

    • Search Google Scholar
    • Export Citation
  • 151

    Boccardo F, Rubagotti A, Puntoni M. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005;23:51385147.

    • Search Google Scholar
    • Export Citation
  • 152

    Boccardo F, Rubagotti A, Guglielmini P. Switching to anastrozole versus continued treatment of early breast cancer. Updated results of the Italian Tamoxifen Anastrozole (ITA) trial. Ann Oncol 2006;17(Suppl 7):vii1014.

    • Search Google Scholar
    • Export Citation
  • 153

    Coombes RC, Hall E, Gibson LJ. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004;350:10811092.

    • Search Google Scholar
    • Export Citation
  • 154

    Jakesz R, Jonat W, Gnant M. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years’ adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;366:455462.

    • Search Google Scholar
    • Export Citation
  • 155

    Jonat W, Gnant M, boccardo F. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta-analysis. Lancet Oncol 2006;7:991996.

    • Search Google Scholar
    • Export Citation
  • 156

    Goss PE, Ingle JN, Martino S. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:17931802.

    • Search Google Scholar
    • Export Citation
  • 157

    Goss PE, PE, Ingle JN, Pater JL. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008;26:19481955.

    • Search Google Scholar
    • Export Citation
  • 158

    Whelan TJ, Goss PE, Ingle JN. Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 2005;23:69316940.

    • Search Google Scholar
    • Export Citation
  • 159

    Perez EA, Josse RG, Pritchard KI. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 2006;24:36293635.

    • Search Google Scholar
    • Export Citation
  • 160

    Braverman AS, Sawhney H, Tendler A. Pre-menopausal serum estradiol (E2) levels may persist after chemotherapy (CT)-induced amenorrhea in breast cancer (BC) [abstract]. Proc Am Soc Clin Oncol 2002;21:Abstract 164.

    • Search Google Scholar
    • Export Citation
  • 161

    Smith IE, Dowsett M, Yap YS. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhoea: caution and suggested guidelines. J Clin Oncol 2006;24:24442447.

    • Search Google Scholar
    • Export Citation
  • 162

    Erban JK, Lau J. On the toxicity of chemotherapy for breast cancer—the need for vigilance. J Natl Cancer Inst 2006;98:10961097.

  • 163

    Early Breast Cancer Trialists’ Collaborative Group Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 1998;352:930942

    • Search Google Scholar
    • Export Citation
  • 164

    Wood WC, Budman DR, Korzun AH. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:12531259.

    • Search Google Scholar
    • Export Citation
  • 165

    Menard S, Valagussa P, Pilotti S. Response to cyclophosphamide, methotrexate, and fluorouracil in lymph node-positive breast cancer according to HER2 overexpression and other tumor biologic variables. J Clin Oncol 2001;19:329335.

    • Search Google Scholar
    • Export Citation
  • 166

    Muss HB, Thor AD, Berry DA. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med 1994;330:12601266.

    • Search Google Scholar
    • Export Citation
  • 167

    Bang SM, Heo DS, Lee KH. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma. Cancer 2000;89:25212526.

    • Search Google Scholar
    • Export Citation
  • 168

    Fisher B, Anderson S, Tan-Chiu E. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-23. J Clin Oncol 2001;19:931942.

    • Search Google Scholar
    • Export Citation
  • 169

    Fisher B, Brown AM, Dimitrov NV. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:14831496.

    • Search Google Scholar
    • Export Citation
  • 170

    Fisher B, Anderson S, Wickerham DL. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-22. J Clin Oncol 1997;15:18581869.

    • Search Google Scholar
    • Export Citation
  • 171

    Henderson IC, Berry DA, Demetri GD. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 2003;21:976983.

    • Search Google Scholar
    • Export Citation
  • 172

    Mamounas EP, Bryant J, Lembersky B. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005;23:36863696.

    • Search Google Scholar
    • Export Citation
  • 173

    Citron ML, Berry DA, Cirrincione C. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: first report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:14311439.

    • Search Google Scholar
    • Export Citation
  • 174

    Levine MN, Pritchard KI, Bramwell VH. Randomized trial comparing cyclophosphamide, epirubicin, and fluorouracil with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer: update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 2005;23:51665170.

    • Search Google Scholar
    • Export Citation
  • 175

    French Adjuvant Study Group. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2001;19:602611.

    • Search Google Scholar
    • Export Citation
  • 176

    Piccart MJ, Di Leo A, Beauduin M. Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer. J Clin Oncol 2001;19:31033110.

    • Search Google Scholar
    • Export Citation
  • 177

    Roche H, Fumoleau P, Spielmann M. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 trial. J Clin Oncol 2006;24:56645671.

    • Search Google Scholar
    • Export Citation
  • 178

    Martin M, Pienkowski T, Mackey J. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:23022313.

  • 179

    Sparano JA, Wang M, Martino S. Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 2008;358:16631671.

  • 180

    Sparano JA, Wang M, Martino S. Phase III study of doxorubicin-cyclophosphamide followed by paclitaxel or docetaxel given every 3 weeks or weekly in patients with axillary node-positive or high-risk node negative breast cancer [abstract]. Presented at the San Antonio Breast Cancer Symposium; December 8–11, 2005; San Antonio, Texas. Abstract 48.

    • Search Google Scholar
    • Export Citation
  • 181

    Jones S, Holmes F, O’Shaughnessey J. Extended follow-up and analysis of the US Oncology Adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older. San Antonio Breast Cancer Symposium; December 13–16, 2007; San Antonio, Texas. Abstract 12.

    • Search Google Scholar
    • Export Citation
  • 182

    Burstein HJ. The distinctive nature of HER2-positive breast cancers. N Engl J Med 2005;353:16521654.

  • 183

    Perez EA, Romond EH, Suman VJ. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/without trastuzumab in patients with HER2-positive breast cancer [abstract]. J Clin Oncol 2007;25(Suppl 1):Abstract 512.

    • Search Google Scholar
    • Export Citation
  • 184

    Tan-Chiu E, Yothers G, Romond E. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005;23:78117819.

    • Search Google Scholar
    • Export Citation
  • 185

    Perez EA, Suman VJ, Davidson NE. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North American Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26:12311238.

    • Search Google Scholar
    • Export Citation
  • 186

    Geyer CE, Bryant JL, Romond MS. Update of cardiac dysfunction on NSABP-31, a randomized trial of sequential doxorubicin/cyclophosphamide (AC) paclitaxel (T) vs. AC T with trastuzumab (H). J Clin Oncol 2006;24(Suppl 1):Abstract 581.

    • Search Google Scholar
    • Export Citation
  • 187

    Telli ML, Hunt SA, Carlson RW, Guardino AE. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility. J Clin Oncol 2007;25:35253533.

    • Search Google Scholar
    • Export Citation
  • 188

    Smith I, Procter M, Gelber RD. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomized controlled trial. Lancet 2007:369:2936.

    • Search Google Scholar
    • Export Citation
  • 189

    Norris B, Chia S, Cheang M. Poor 10 yr breast cancer specific survival and relapse free survival for HER2-positive T1pN0 tumors. San Antonio Breast Cancer Symposium; December 10–14, 2006; San Antonio, Texas. Abstract 2031.

    • Search Google Scholar
    • Export Citation
  • 190

    Untch M, Gelber RD, Jackisch C. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008;19:10901096.

    • Search Google Scholar
    • Export Citation
  • 191

    Hortobagyi GN, Singletary SE, Strom EA. Locally advanced breast cancer. In: Harris JR, Lippman ME, Morrow M, Osborne CK, eds. Diseases of the Breast. 3rd ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2004.

    • Search Google Scholar
    • Export Citation
  • 192

    Rosselli Del Turco M, Palli D, Cariddi A. Intensive diagnostic follow-up after treatment of primary breast cancer. A randomized trial. National Research Council Project on Breast Cancer Follow-Up. JAMA 1994;271:15931597.

    • Search Google Scholar
    • Export Citation
  • 193

    Smith TJ, Davidson NE, Schapira DV. American Society of Clinical Oncology 1998 update of recommended breast cancer surveillance guidelines. J Clin Oncol 1999;17:10801082.

    • Search Google Scholar
    • Export Citation
  • 194

    The GIVIO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized controlled trial. JAMA 1994;271:15871592.

    • Search Google Scholar
    • Export Citation
  • 195

    Bast RC Jr, Ravdin P, Hayes DF. 2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001;19:18651878.

    • Search Google Scholar
    • Export Citation
  • 196

    Kirova YM, Stoppa-Lyonnet D, Savignoni A. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy. Eur J Cancer 2005;41:23042311.

    • Search Google Scholar
    • Export Citation
  • 197

    Pierce LJ, Levin AM, Rebbeck TR. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer. J Clin Oncol 2006;24:24372443.

    • Search Google Scholar
    • Export Citation
  • 198

    Metcalfe K, Lynch HT, Ghadirian P. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol 2004;22:23282335.

  • 199

    American College of Obstetrics and Gynecology Committee on Gynecologic Practice. ACOG Committee Opinion. No. 336: tamoxifen and uterine cancer. Obstet Gynecol 2006;107:14751478.

    • Search Google Scholar
    • Export Citation
  • 200

    Loprinzi CL, Kugler JW, Sloan JA. Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial. Lancet 2000;356:20592063.

    • Search Google Scholar
    • Export Citation
  • 201

    Garber K. Tamoxifen pharmacogenetics moves closer to reality. J Natl Cancer Inst 2005;97:412413.

  • 202

    Jin Y, Desta Z, Stearns V. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005;97:3039.

    • Search Google Scholar
    • Export Citation
  • 203

    Hillner BE, Ingle JN, Chlebowski RT. American Society of Clinical Oncology 2003 Update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003;21:40424057.

    • Search Google Scholar
    • Export Citation
  • 204

    Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487497.

  • 205

    Eubank WB, Mankoff D, Bhattacharya M. Impact of FDG PET on defining the extent of disease and on the treatment of patients with recurrent or metastatic breast cancer. AJR Am J Roentgenol 2004;183:479486.

    • Search Google Scholar
    • Export Citation
  • 206

    Moon DH, Maddahi J, Silverman DH. Accuracy of whole-body fluorine-18-FDG PRT for the detection of recurrent or metastatic breast carcinoma. J Nucl Med 1998;39:431435.

    • Search Google Scholar
    • Export Citation
  • 207

    Vernon CC, Hand JW, Field SB. Radiotherapy with or without hyperthermia in the treatment of superficial localized breast cancer: results from five randomized controlled trials. International Collaborative Hyperthermia Group. Int J Radiat Oncol Biol Phys 1996;35:731744.

    • Search Google Scholar
    • Export Citation
  • 208

    Jones EL, Oleson JR, Prosnitz LR. Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol 2005;23:30793085.

  • 209

    Higgins MJ, Wolff AC. Therapeutic options in the management of metastatic breast cancer. Oncology 2008;22:614623; discussion 623, 627–629.

    • Search Google Scholar
    • Export Citation
  • 210

    Theriault RL, Biermann JS, Brown E. NCCN Task Force Report: Bone Health and Cancer Care. J Natl Compr Canc Netw 2006;(4 Suppl 2):S120.

  • 211

    Conte PF, Latreille J, Mauriac L. Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group. J Clin Oncol. 1996;14:25522559.

    • Search Google Scholar
    • Export Citation
  • 212

    Hortobagyi GN, Theriault RL, Lipton A. Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16:20382044.

    • Search Google Scholar
    • Export Citation
  • 213

    Theriault RL, Lipton A, Hortobagyi GN. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846854.

    • Search Google Scholar
    • Export Citation
  • 214

    Berenson JR, Rosen LS, Howell A. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001;91:11911200.

    • Search Google Scholar
    • Export Citation
  • 215

    Ali SM, Esteva FJ, Hortobagyi G. Safety and efficacy of bisphosphonates beyond 24 months in cancer patients. J Clin Oncol 2001;19:34343437.

  • 216

    Theriault RL. The role of bisphosphonates in breast cancer. J Natl Compr Canc Netw 2003;1:232241.

  • 217

    Rosen LS, Gordon D, Kaminski M. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377387.

    • Search Google Scholar
    • Export Citation
  • 218

    Rosen LS, Gordon DH, Dugan W Jr. Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100:3643.

    • Search Google Scholar
    • Export Citation
  • 219

    Lipton A, Theriault RL, Hortobagyi GN. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:10821090.

    • Search Google Scholar
    • Export Citation
  • 220

    Hortobagyi GN, Theriault RL, Porter L. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:17851971.

    • Search Google Scholar
    • Export Citation
  • 221

    Diel IJ, Body JJ, Lichinitser MR. Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 2004;40:17041712.

    • Search Google Scholar
    • Export Citation
  • 222

    McLachlan SA, Cameron D, Murray R. Safety of oral ibandronate in the treatment of bone metastases from breast cancer: long-term follow-up experience. Clin Drug Investig 2006;26:4348.

    • Search Google Scholar
    • Export Citation
  • 223

    Pecherstorfer M, Rivkin S, Body JJ. Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. Clin Drug Investig 2006;26:315322.

    • Search Google Scholar
    • Export Citation
  • 224

    Lipton A, Theriault RL, Hortobagyi GN. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:10821090.

    • Search Google Scholar
    • Export Citation
  • 225

    Rosen LS, Gordon D, Kaminski M. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:17351744.

    • Search Google Scholar
    • Export Citation
  • 226

    Wilkinson GS, Kuo YF, Freeman JL, Goodwin JS. Intravenous bisphosphonate therapy and inflammatory conditions or surgery of the jaw: a population-based analysis. J Natl Cancer Inst 2007;99:10161024.

    • Search Google Scholar
    • Export Citation
  • 227

    Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Systematic Review Bisphosphonates Osteonecrosis of the Jaw. Ann Intern Med 2006;144:753761.

    • Search Google Scholar
    • Export Citation
  • 228

    Buzdar A, Douma J, Davidson N. Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001;19:33573366.

    • Search Google Scholar
    • Export Citation
  • 229

    Buzdar AU, Jonat W, Howell A. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 1998;83:11421152.

    • Search Google Scholar
    • Export Citation
  • 230

    Bonneterre J, Thurlimann B, Robertson JF. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:37483757.

    • Search Google Scholar
    • Export Citation
  • 231

    Nabholtz JM, Buzdar A, Pollak M. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:37583767.

    • Search Google Scholar
    • Export Citation
  • 232

    Vergote I, Bonneterre J, Thurlimann B. Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. Eur J Cancer 2000;36(Suppl 4):S8485.

    • Search Google Scholar
    • Export Citation
  • 233

    Paridaens R, Therasse P, Dirix L. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (T) in postmenopausal patients (pts)—a randomized phase III trial of the EORTC Breast Group [abstract]. J Clin Oncol 2004;22:14S (Suppl 1):Abstract 515.

    • Search Google Scholar
    • Export Citation
  • 234

    Klijn JG, Blamey RW, Boccardo F. Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: a meta-analysis of four randomized trials. J Clin Oncol 2001;19:343353.

    • Search Google Scholar
    • Export Citation
  • 235

    Osborne CK, Pippen J, Jones SE. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:33863395.

    • Search Google Scholar
    • Export Citation
  • 236

    Howell A, Robertson JF, Quaresma Albano J. Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:33963403.

    • Search Google Scholar
    • Export Citation
  • 237

    Robertson JF, Osborne CK, Howell A. Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003;98:229238.

    • Search Google Scholar
    • Export Citation
  • 238

    Ingle JN, Suman VJ, Rowland KM. Fulvestrant in women with advanced breast cancer after progression on prior aromatase inhibitor therapy: North Central Cancer Treatment Group Trial N0032. J Clin Oncol 2006;24:10521056.

    • Search Google Scholar
    • Export Citation
  • 239

    Chia S, Gradishar W, Mauriac L. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008;26:16641670.

    • Search Google Scholar
    • Export Citation
  • 240

    Lonning PE, Bajetta E, Murray R. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000;18:22342244.

    • Search Google Scholar
    • Export Citation
  • 241

    Dombernowsky P, Smith I, Falkson G. Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 1998;16:453461.

    • Search Google Scholar
    • Export Citation
  • 242

    Buzdar A, Jonat W, Howell A. Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. J Clin Oncol 1996;14:20002011.

    • Search Google Scholar
    • Export Citation
  • 243

    Carrick S, Parker S, Wilcken N. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev 2005;2:CD003372.

    • Search Google Scholar
    • Export Citation
  • 244

    Sledge GW, Neuberg D, Bernardo P. Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an Intergroup trial (E1193). J Clin Oncol 2003;21:588592.

    • Search Google Scholar
    • Export Citation
  • 245

    O’Shaughnessy J, Miles D, Vukelja S. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:28122823.

    • Search Google Scholar
    • Export Citation
  • 246

    Albain K, Nag S, Calderillo-Ruiz J. Global phase III study of gemcitabine plus paclitaxel (GT) vs. paclitaxel (T) as frontline therapy for metastatic breast cancer. (MBC): First report of overall survival [abstract]. J Clin Oncol 2004;22:14s(Suppl 1):Abstract 510.

    • Search Google Scholar
    • Export Citation
  • 247

    Muss HB, Case LD, Richards F II. Interrupted versus continuous chemotherapy in patients with metastatic breast cancer. The Piedmont Oncology Association. N Engl J Med 1991:325;13421348.

    • Search Google Scholar
    • Export Citation
  • 248

    Falkson G, Gelman R, Pandya K. Eastern Cooperative Oncology Group randomized trials of observation versus maintenance therapy for patients with metastatic breast cancer in complete remission following induction treatment. J Clin Oncol 1998;16:16691676.

    • Search Google Scholar
    • Export Citation
  • 249

    Miller KD, Wang M, Gralow J. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:26662676.

    • Search Google Scholar
    • Export Citation
  • 250

    Roche H, Yelle L, Cognetti F. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25:34153420.

    • Search Google Scholar
    • Export Citation
  • 251

    Thomas E, Tabernero J, Fornier M. Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007;25:33993406.

    • Search Google Scholar
    • Export Citation
  • 252

    Perez EA, Lerzo G, Pivot X. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:34073414.

    • Search Google Scholar
    • Export Citation
  • 253

    Thomas ES, Gomez HL, Li RK. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol 2007;25:52105217.

    • Search Google Scholar
    • Export Citation
  • 254

    Seidman AD, Berry D, Cirrincione C. Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER2 overexpressors and random assignment to trastuzumab or not in HER2 nonoverexpressors: final results of Cancer and Leukemia Groups B protocol 9840. J Clin Oncol 2008;26:16421649.

    • Search Google Scholar
    • Export Citation
  • 255

    Roche PC, Suman VJ, Jenkins RB. Concordance between local and central laboratory HER2 testing in the breast Intergroup trial N9831. J Natl Cancer Inst 2002;94:855857.

    • Search Google Scholar
    • Export Citation
  • 256

    Robert N, Leyland-Jones B, Asmar K. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol 2006;24:27862792.

    • Search Google Scholar
    • Export Citation
  • 257

    Burstein HJ, Keshaviah A, Baron AD. Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007;110:965972.

    • Search Google Scholar
    • Export Citation
  • 258

    Yamamoto D, Iwase S, Kitamura K. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network 00 trial. Cancer Chemother Pharmacol 2008;61:509514.

    • Search Google Scholar
    • Export Citation
  • 259

    Schaller G, Bangemann N, Weber J. Efficacy and safety of trastuzumab plus capecitabine in a German multicentre phase II study of pre-treated metastatic breast cancer [abstract]. J Clin Oncol 2005;23:18(Suppl 1):Abstract 717.

    • Search Google Scholar
    • Export Citation
  • 260

    Seidman A, Hudis C, Pierri MK. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:12151221.

  • 261

    Bartsch R, Wenzel C, Altorjai G. Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 2007;25:38533858.

    • Search Google Scholar
    • Export Citation
  • 262

    Von Minckwitz G, Vogel P, Schmidt M. Trastuzumab treatment beyond progression in patients with HER2 positive metastatic breast cancer—interim report [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 4056.

    • Search Google Scholar
    • Export Citation
  • 263

    Von Minckwitz G, Zielinski C, Maarteense E. Capecitabine vs. Capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: the TBP phase III study (GBG 26/BIG 3-05) [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 1025.

    • Search Google Scholar
    • Export Citation
  • 264

    Geyer CE, Forster J, Lindquist D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:27332743.

  • 265

    O’Shaughnessy J, Blackwell KL, Burstein H. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy [abstract]. J Clin Oncol 2008;26(Suppl 1):Abstract 1015.

    • Search Google Scholar
    • Export Citation
  • 266

    Hortobagyi GN. Multidisciplinary management of advanced primary and metastatic breast cancer. Cancer 1994;74:416423.

  • 267

    Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery 2002;132:620627.

  • 268

    Babiera GV, Rao R, Feng L. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol 2006;13:776782.

    • Search Google Scholar
    • Export Citation
  • 269

    Rapiti E, Verkooijen HM, Vlastos G. Complete excision of primary breast tumor improves survival of patients with metastatic breast cancer at diagnosis. J Clin Oncol 2006;24:27432749.

    • Search Google Scholar
    • Export Citation
  • 270

    Rao R, Feng L, Kuerer HM. Timing of surgical intervention for the intact primary in stage IV breast cancer patients. Ann Surg Oncol 2008;15:16961702.

    • Search Google Scholar
    • Export Citation
  • 271

    Morrow M, Goldstein LJ. Surgery of the primary tumor in metastatic breast cancer: closing the barn door after the horse has bolted? J Clin Oncol 2006;24:26942696.

    • Search Google Scholar
    • Export Citation
  • 272

    Olson JA, Marcom PK. Benefit or bias? The role of surgery to remove the primary tumor in patients with metastatic breast cancer. Ann Surg 2008;247:739740.

    • Search Google Scholar
    • Export Citation
  • 273

    Jaiyesimi IA, Buzdar AU, Hortobagyi G. Inflammatory breast cancer: a review. J Clin Oncol 1992;10:10141024.

  • 274

    Dawood S, Cristofanilli M. What progress have we made in managing inflammatory breast cancer? Oncology 2007;21:673687.

  • 275

    Greene FL, Page DL, Fleming ID. AJCC Cancer Staging Manual. 6th ed. New York, NY: Springer-Verlag; 2002.

  • 276

    Haagensen CD. Inflammatory carcinoma. In: Haagensen CD, ed. Diseases of the Breast. Philadelphia, PA: WB Saunders,